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ervical  and  mediastinal  lymph-node  management  diffe-
entiated  thyroid  carcinoma  of  the  follicular  epithelium
DTC)  remains  controversial.  Depending  on  the  situation,
re-operative  staging  and  indications  for  and  extent  of
ymph-node  dissection  are  still  matters  of  debate,  even  in
ase  of  palpable  nodes  found  on  primary  surgery.  Procedu-
al  indications  for  adenectomy,  selective  neck  dissection,
.
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nd  anatomic  regional  extension  of  dissection  are  not  clearly
eﬁned.  Attitudes  in  suspected  recurrence  during  follow-up
eed  to  be  laid  down.
The  principles  of  DTC  management  in  France  are  founded
n  the  French  Endocrinology  Society  (Société  Franc¸aise
’Endocrinologie) 2007  guidelines  for  the  management  of
TC  of  vesicular  origin  [1]  (consensus  guidelines),  the  2006
nd  2009  American  Thyroid  Association  guidelines  [2,3]
consensus  guidelines),  and  the  good  practice  guide  for
ervical  ultrasound  scan  and  echo-guided  techniques  in
reating  differentiated  thyroid  cancer  of  vesicular  origin  [4]
consensus  guidelines).  To  formalize  the  rules  for  manage-
ent  of  lymph-node  involvement  in  DTC,  the  French  ENT
 Head  Neck  Surgery  Society  (Société  Franc¸aise  d’Oto-
hino-Laryngologie  et  de  Chirurgie  de  la  Face  et  du  Cou:
FORL)  called  upon  contributions  from  lymph-node  special-
st  teams  to  a  joint  set  of  guidelines  drawn  up  with  the
rench  Societies  of  Nuclear  Medicine  and  Molecular  Imag-
ng  (Société  Franc¸aise  de  Médecine  Nucléaire  et  d’Imagerie
oléculaire), Radiology  (Société  Franc¸aise  de  Radiologie)
nd  Pathology  (Société  Franc¸aise  de  Pathologie)1.
The  present  guidelines  are  a  logical  formalization  of
oncepts  and  practices  regarding  lymph-node  management
trategies  in  DTC.  They  are  intended  for  surgeons  special-
zed  in  thyroid  pathology,  but  also  for  physicians  managing
TC  patients.
The  full  text,  including  rationale  and  extended  refe-
ence  list,  is  available  on-line  on  the  SFORL  website
http://www.orlfrance.org/  download.php?id=159).
ethod
FORL-member  experts  were  appointed  by  the  guidelines
teering  committee.  Each  of  the  participating  societies
sked  its  expert  members  to  take  part  in  a  work  group,
hich  met  several  times  during  the  process  of  drawing  up
he  guidelines.  A  review  group,  independent  of  the  work
roup,  read  over  the  draft  guidelines.  The  ﬁnal  version  was
greed  upon  at  an  editorial  meeting.
evel of evidence and recommendations grade
he  literature  analysis  used  levels  of  evidence,  according
o  the  French  Health  Authority  (HAS)  2000  guidelines.  The
arious  recommendations  were  graded  on  a  modiﬁed  version
f  the  Sackett  Score  (Table  1).
uestions raised in the guidelineshe  steering  committee  drew  up  a  list  of  questions  for  the
ork  group  to  address  in  their  guidelines.
The  questions  concerning  lymph-node  involvement  prog-
osis  are  as  follows:
1 The French Society of Endocrinology (Société Franc¸aise
’Endocrinologie) and French-speaking Association of Endocrine
urgery (Association Francophone de Chirurgie Endocrinienne) took
art in the editing process.
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 what  is  lymph-node  involvement  in  DTC?
 what  information  can  anatomopathologic  lymph-node
examination  provide?
what  is  the  prognostic  value  of  lymph-node  invasion:  for
recurrence,  and  for  survival?
The  question  concerning  complementary  examinations
nd  assessment  in  primary  management  are:
what  baseline  assessment  is  required  ahead  of  treatment
of  papillary  thyroid  carcinoma  to  assess  possible  lymph-
node  involvement?
◦  in  morphologic  imaging,
◦  in  cytology,
◦ in isotopic  imaging.
The  questions  concerning  neck  dissection  are:
 what  are  the  principles  of  lymph-node  surgery?  Central
and  lateral  dissection,  and  dissection  extended  to  the
mediastinum;
 what  is  the  iatrogenesis  in  cN0  and  cN+  neck?
 what  is  the  impact  of  central  and  lateral  neck  dissection
on  recurrence,  survival,  secondary  treatment  and  surveil-
lance  in  cN0  and  cN+  ?
 in  cN0  patients,  when  neck  dissection  is  considered,  what
lymph-node  regions  should  be  indicated?
 in  IIA  invasion,  what  should  be  the  attitude  regarding  IIB?
 when  should  neck  dissection  be  bilateral,  electively  and
mandatorily?
what  is  the  role  of  the  sentinel  node  (SN)  technique?
what  role  is  there  for  extensive  cervico-mediastinal  dis-
section?
hat is the role of 131I in primary treatment
f  adenopathy?
he  questions  concerning  particular  situations  are:
 When  a  papillary  microcarcinoma  is  discovered,  what
should  be  the  attitude,  per-operatively  and  postopera-
tively,  toward  the  lymph-nodes  areas?
 are  some  histologic  forms  of  papillary  cancer  more  aggres-
sive  than  others,  and  therefore  requiring  more  extensive
ﬁrst-line  neck  dissection?
 in  case  of  recurrence  or  of  refractory  cancer:
◦  what  is  the  role  of  Positron  emission  tomography  with
18-ﬂuoro-2-deoxyglucose  (PET-CT)  imaging?
◦  what  are  the  indications  for  morphologic  imaging?
◦  what  is  the  role  of  ﬁne-needle  aspiration  cytology?
◦  what  surgical  procedure  should  be  performed?
◦  with  what  precautions?
◦  what  risks  are  involved?
◦  what  are  the  other  aspects  of  treatment?
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Table  1  Levels  of  evidence  and  recommendation  grades.
Level  of  evidence  according  to  the  literature  Recommendation  grade
Level  1  Grade  A
High-power  randomized  comparative  trials Established  scientiﬁc  proof
Meta-analysis  of  randomized  comparative  trials
Decision  analysis  based  on  well-conducted  studies
Level  2  Grade  B
Low-power  randomized  comparative  trial Scientiﬁc  presumption
Non-randomized  well-conducted  studies
Cohort  studies
Level  3 Grade  C
Case-control  studies Low  level  of  evidence
Retrospective  comparative  studies
Level  4
Comparative  studies  with  serious  bias
Retrospective  studies
Case  series
Descriptive  (transversal,  longitudinal)  epidemiological  studies
Other  publication  (case  report,  expert  opinion,  etc.) Consensus  guidelinesa
No  publication
Correspondence between literature assessment and recommendation grades (adapted from Sackett Score) according to the HAS Literature
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a Unless otherwise stated, recommendations here correspond to
Guidelines
Questions  concerning  lymph-node  involvement
prognosis
What  is  lymph-node  involvement  in  differentiated
thyroid  carcinoma?
Prognosis  of  lymph-node  involvement  in  follicular  DTC  is  con-
troversial.
The  following  deﬁnitions  are  to  be  borne  in  mind:
•  clinical  stage  N0  (cN0):  no  (clinical  or  radiological)  pre-
operative  lymph-node  involvement;
•  lymph-node  metastasis  (pN1  or  +):  200  m-2  mm  intra-
nodal  tumor  tissue,  micrometastasis;  more  than  2  mm,
macrometastasis;  less  than  200  m,  isolated  tumor  cells
(of  no  known  prognostic  value)  [5];
•  occult  lymph-node  metastasis  (cN0-pN+).  This  term  is
ambiguous,  covering  lymph-node  metastases  not  diag-
nosed  on  pre-  or  per-operative  assessment,  but  of  greatly
varying  sizes  and  whatever  the  type  or  value  of  the  assess-
ment.
Micrometastasis  is  not  detected  in  routine  practice,  as
it  requires  a  large  number  of  cross-sections  per  node  and
immunostaining  (e.g.,  the  SN  technique)  [6]  (level  of  evi-
dence,  4)  [7]  (level  of  evidence,  2).Metastatic  lymph-node  involvement  is  very  frequent  in
DTC,  but  often  underestimated,  both  in  clinical  practice  and
in  the  literature.  Histopathologically,  the  rate  of  pN+  varies
from  15%  to  60%  [8]  (level  of  evidence,  4)  and  may  reach
D
t
[ante.fr/portail/upload/docs/application/pdf/analiterat.pdf.
ensus guidelines.
0%  [9]  (level  of  evidence,  4),  depending  on  the  degree  of
recision  of  lymph-node  work-up.
hat  factors  are  relevant  to  prognosis?
ymph-node  invasion  impacts  both  locoregional  recurrence
nd  survival.  The  relative  risk  of  mortality  in  DTC  associated
ith  lymph-node  metastasis  is  1.9  [10]  (level  of  evidence,
).  pN+  disease  was  associated  with  elevated  rates  of  recur-
ence  and  of  mortality  in  30-year  follow-up  studies  [11]
level  of  evidence,  4).
Diagnosis  of  lymph-node  metastasis  reclassiﬁes  DTC
atients  over  the  age  of  45  years  from  AJCC  stage  I to  stage
II  [12]  (level  of  evidence,  4).  Thus,  in  case  of  pN+  in  T1N0
ancer,  iodine  131  (131I)  is  recommended  in  30%  of  patients
13]  (level  of  evidence,  4)  [1]  (consensus  guidelines).
Recommendation  1
Infraclinical  lymph-node  involvement  should  be
taken  into  account  in  micro-  and  macro-metastasis,
as  a  pathological  condition  worsening  prognosis  and
indicating  a  curative  attitude.  Treatment  consequently
does  not  fall  under  the  deﬁnition  of  ‘‘prophylaxis’’
(grade  B).
re-operative  lymph-node  stagingoppler  ultrasound  (US)  is  the  reference  imaging  examina-
ion  in  pre-operative  assessment  and  surveillance  of  DTC
14]  (level  of  evidence,  4),  [2]  [1,4]  (consensus  guidelines),
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Table  2  Ultrasound  signs  of  malignancy.
A  single  major  criterion  is  sufﬁcient
Microcalciﬁcation
Cystic  area
Hyper-echogenicity
Exclusive  or  mixed  peripheral  vascularization  (unless
infection)
Minor  criteria  are  not  decisive  alone
Short  axis  ≥  8  mm
Long/short  axis  <  2
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In  case  of  risk  of  mediastinal  lymph-node  extension,
cervico-thoracic  contrast-enhanced  radiology  exam
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15]  (level  of  evidence,  1),  with  regard  to  detection,  diag-
osis,  exploration  for  signs  of  malignancy  and  surveillance
f  cervical  lymph  nodes.  The  US  data  and  interpretation  of
his  examination  are  detailed  in  the  French  good  practice
uide  [4]  (consensus  guidelines).
Table  2  presents  the  ultrasound  signs  of  malignancy  [16]
consensus  guidelines)  [17]  (level  of  evidence,  4).
Lymph-node  ﬁne-needle  aspiration  cytology  is  recom-
ended  in  suspect  nodes  discovered  on  pre-operative
ssessment  or  during  surveillance  examination,  with  wash-
ut  liquid  thyroglobulin  (Tg)  assay  as  required  [4]  (consensus
uidelines).
Recommendation  2
A.  In  thyroid  ultrasound  examination,  especially
when  pre-operative,  all  cervical  lymph-node  areas
should  be  analyzed  (grade  A).
B.  In  proven  or  suspected  thyroid  cancer,  complete
pre-operative  US  mapping  of  all  cervical  lymph-node
areas  is  recommended  (grade  A).
Recommendation  3
A.  In  case  of  non-characteristic  radio-clinical  pre-
sentation  on  initial  assessment,  ﬁne-needle  aspiration
cytology  associated  to  in  situ  wash-out  liquid  Tg  assay
is  highly  contributive  (Expert  opinion).
B.  In  post-treatment  follow-up  of  thyroid  cancer,
ﬁne-needle  aspiration  cytology  is  recommended:
in  case  of  any  major  US  malignancy  criterion:
microcalciﬁcation,  cystic  area,  hyperechogenicity,  or
exclusive  or  mixed  peripheral  vascularization  (except
when  associated  with  infection);
or  in  case  of  at  least  two  minor  criteria:  short  axis
more  or  equal  to  8  mm,  long/short  axis  ratio  less  than
2,  absence  of  visible  hilum.
C.  In  lateral  compartment  nodes,  ﬁne-needle  aspi-
ration  cytology  should  be  completed  by  nodal  biopsy
liquid  Tg  assay  (grade  B).should  be  performed  (grade  B).
Iodized  contrast  medium  injection  for  CT  precludes
adio-iodine  therapy  for  6—8  weeks.
Postoperative  and  post-treatment 131I scintigraphy  is
 whole-body  planar  imaging  technique.  Interpretation  is
igniﬁcantly  improved  by  hybrid  SPECT-CT  (single  proton
mission  computed  tomography—computed  tomography)
18].
Recommendation  5
In  case  of  radio-iodine  therapy,  SPECT-CT  is  recom-
mended,  as  the  optimal  imaging  technique  for  lymph-
node  staging,  especially  during  the  ﬁrst  3  postoperative
months,  in  preference  to  ultrasound.  Staging  inﬂuences
subsequent  management  (grade  B).
PET-CT  should  be  reserved  for  suspected  recurrence
r  persistent  disease,  in  which  cases  it  affects  treatment
ecision-making  in  30—40%  of  cases  [19]  (level  of  evidence,
).
Recommendation  6
During  postoperative  follow-up,  PET-CT  is  recom-
mended  in  case  of  elevated  serum  Tg  with  or  without
suppressive  treatment,  unaccounted  for  by  US  and/or
iodine  scintigraphy  (grade  A).
hat  are  the  aims  and  principles  of  lymph-node
urgery? Concepts  of  central  and  lateral  dissection
he  literature  classically  contrasts  prophylactic  dissection
n  cervical  cN0  (‘‘elective  neck  dissection’’)  and  therapeu-
ic  dissection  in  clinical  cervical  adenopathy  (‘‘modiﬁed
adical  neck  dissection’’).  However,  infraclinical  lymph-
ode  metastasis  (cN0-pN+)  is  of  poor  prognosis,  and
issection  is  therefore  more  therapeutic  than  prophylactic.
e  therefore  advise  the  terms  ‘‘elective  dissection’’  in  cer-
ical  cN0  and  ‘‘mandatory  dissection’’  in  clinical  cervical
denopathy;  this  semantic  distinction  is  important  in  order
o  avoid  certain  mistakes  of  management  in  cervical  cN0.
Recommendation  7
In  clinical  central  adenopathy,  node  picking  (resect-
ing  just  the  clinical  adenopathy)  is  not  recommended
but  rather,  if  conditions  permit,  full-scale  dissection
(grade  A).
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Recommendation  8
In  cN0,  surgical  exploration  of  the  central  compart-
ment  is  of  little  diagnostic  use.  Two  strategies  are
recommended:  full-scale  dissection  of  one  or  several
lymph-node  levels,  or  abstention  from  any  lymph-node
surgery  (grade  B).
Recommendation  9
Extemporaneous  analysis  of  a  lymph  node  can
establish  only  a  positive  result,  but  cannot  rule  out
Figure  1  MacFee  incision  scar:  enlarged  lower  cervicotomy
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[lymph-node  metastasis  (grade  A).
The  central  compartment  thus  corresponds  to  Robbins’
level  VI  [20]  (level  of  evidence,  4).  It  contains  bilateral
prelaryngeal,  pretracheal  and  paratracheal  nodes.  Dissec-
tion  is  unilateral  when  it  spares  the  paratracheal  nodes
contralateral  to  the  tumor.
Recommendation  10
‘‘Unilateral’’  central  compartment  dissection  con-
sists  in  complete  dissection  of  prelaryngeal,  pretra-
cheal  and  paratracheal  nodes  on  a  single  side,  whether
right  or  left.
‘‘Bilateral’’  central  compartment  dissection  con-
sists  in  complete  dissection  of  prelaryngeal,  pretra-
cheal  and  paratracheal  nodes  on  both  sides.
These  terms  should  be  used  for  procedural  descrip-
tions  (grade  B).
Recommendation  11
Surgical  specimens  should  be  sent  to  the  anato-
mopathology  laboratory  labelled  according  to  the
Robbins  classiﬁcation  (grade  A).
It  should  be  borne  in  mind  that  oncologic  and  functional
results  are  operator-dependent  [21]  (level  of  evidence,  4).
Lateral  dissection  concerns  lymph-node  levels  I  to  V.
Its  extent  and  whether  it  is  to  be  uni-  or  bi-lateral  and
the  various  surgical  approaches  vary  from  team  to  team
and  according  to  clinical  situation.  MacFee’s  staged  incision
gives  very  good  cosmetic  results  [22]  (Fig.  1).Recommendation  12
In  primary  surgery,  central  dissection  must  precede
any  lateral  dissection  (expert  opinion).
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Tf thyroidectomy  (lower  arrow-head)  and  mid-cervical  contra-
ncision  (upper  arrow-head),  according  to  Uchino  et  al.  [22]
level  of  evidence,  4).  Courtesy  of  Dr  Cartier.
Recommendation  13
A.  The  scar  left  by  lateral  dissection  is  a  problem
for  both  surgeon  and  patient.  There  are  no  data  in
the  literature  recommending  one  incision  rather  than
another  (grade  B).
B.  In  cervical  cN0,  MacFee’s  staged  incision  pro-
vides  sufﬁcient  operative  exposure,  with  a  very  good
cosmetic  result  (expert  opinion).
Recommendation  14
Radical  neck  dissection  is  not  advised  in  thyroid
cancer,  other  than  in  case  of  exceptionally  large
adenopathy,  massive  capsule  rupture  or  invasion  of
neighboring  structures  seen  on  pre-operative  imaging
(expert  opinion).
The  levels  affected  in  lateral  cervical  cN0  are  IIa,  III  and
V,  which  should  therefore  be  included  in  elective  dissection
23—25]  (level  of  evidence,  4).
Recommendation  15
In  elective  lateral  compartment  dissection  —  i.e.,  in
clinically  negative  lateral  compartments—levels  IIa,  III
and  IV  should  be  dissected.  Extension  to  levels  IIb  and  V
is  recommended  only  when  their  involvement  has  been
demonstrated  histologically  (grade  C).
The  SN  technique  has  been  validated  in  DTC  [7]  (level
f  evidence,  2)  [26,27]  (level  of  evidence,  4).  It  is  applica-
le  only  in  cN0  neck  [7]  (level  of  evidence,  2).  It  consists
n  intrathyroid  radiotracer  injection,  lymphoscintigraphic
maging,  selective  dissection  guided  by  handled  detection
robe,  and  deﬁnitive  anatomopathologic  analysis  of  serial
tep  sections  with  immunostaining  [7]  (level  of  evidence,  2).
here  are,  however,  no  reports  of  oncologic  or  functional
2r
a
t
c
p
l
s
l
b
s
d
l
m
e
o
c
a
l02  
esults  in  DTC  for  treatment  strategies  founded  on  SN
nalysis.
Recommendation  16
The  SN  technique  is  feasible  in  lymph-node  treat-
ment  in  DTC  (grade  A).
Recommendation  17
The  technique  should  include  intrathyroid  radio-
colloid  injection,  SN  adenectomy  and  deﬁnitive
pathological  analysis  using  serial  step  sections  with
immunostaining  (grade  A).
Recommendation  18
The  SN  technique  should  not  be  applied  in  cN+
(grade  A).
The  pN  stage  can  be  determined  by  neck  dissection  and
he  SN  technique;  this  results  in  the  patient’s  status  being
hanged  and  treatment  strategy  being  readjusted  in  30%  of
atients  [13]  (level  of  evidence,  4).
Recommendation  19
The  nodal  stage  pSN  based  on  the  SN  technique  is
more  precise  than  the  clinical  nodal  stage  cN  (grade
B).
Recommendation  20
There  are  no  data  on  the  therapeutic  impact  of  the
SN  technique;  it  should  be  implemented  in  formalized
clinical  studies  (grade  C).
Regarding  indications,  mandatory  central  dissection
eaves  no  room  for  discussion.
Recommendation  21
Bilateral  central  dissection  is  indicated  in  clini-
cal  cN+  adenopathy,  at  whatever  site,  and  represents
‘‘mandatory’’  dissection.  Ideally,  it  should  be  per-
formed  in  the  same  surgical  step  as  total  thyroidectomy
(grade  A).Elective  dissection  (cN0)  was  accepted  in  recent  consen-
us  documents  [2],  with  the  following  beneﬁt:  prevention  of
ocoregional  recurrence,  improved  survival,  reduced  mor-
idity  associated  with  surgical  revision,  and  facilitation  ofB.  Guerrier  et  al.
ubsequent  treatment  and  follow-up  [28,29]  (level  of  evi-
ence,  4).
Recommendation  22
Uni-  or  bi-lateral  elective  central  neck  dissection  is
strongly  recommended  in  T3  or  T4cN0  tumor  (grade  B).
Recommendation  23
If  it  is  decided  to  totalize  thyroidectomy  in  a  can-
cer  discovered  on  deﬁnitive  histology  (cN0),  there  is
no  recommendation  for  ipsilateral  latero-tracheal  dis-
section,  due  to  elevated  inferior  laryngeal  nerve  palsy
and  parathyroid  gland  risk  and  the  lack  of  sufﬁcient
evidence  for  improved  initial  control  (expert  opinion).
In  central  clinical  involvement  cN1a  without  lateral  signs,
ateral  dissection  on  the  lesional  side  is  strongly  recom-
ended,  as  reducing  the  risk  of  lymph-node  recurrence,
ven  in  low-risk  tumor  [30]  (level  of  evidence,  3)  [31]  (level
f  evidence,  4).
Aggressiveness  criteria  such  as  stage  T3  or  T4  tumor,
apsule  rupture,  age  more  than  55  years  or  presence  of
n  aggressive  variant  are  associated  with  increased  risk  of
ateral  involvement  [32]  (level  of  evidence,  4).
Recommendation  24
In  case  of  central  compartment  lymph-node  invasion
(cN1a)  without  clinical  signs  of  lateral  compartment
involvement,  elective  lateral  dissection  ipsilateral  to
the  thyroid  tumor  is  recommended,  as  the  risk  of  lateral
compartment  involvement  is  elevated  (grade  B).
Recommendation  25
Complete  lateral  dissection  is  indicated  in  case  of
cytologic  or  histologic  proof  of  involvement  of  any
lateral  compartment  node  (grade  B).
Recommendation  26
Elective  dissection  of  the  lateral  compartment  con-
tralateral  to  the  thyroid  tumor  is  indicated  for  pT4
tumor  or  more  than  3  cm  ipsilateral  adenopathy  (grade
C).
Recommendation  27
Depending  on  the  teams  and  practice,  lateral  neck
dissection  may  or  may  not  be  performed  in  cN0  (expert
opinion).
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Recommendation  28
In  locally  aggressive  tumor  or  cN0  aggressive  variant,
elective  lateral  dissection  ipsilateral  to  the  tumor  is
recommended  (grade  C).
Recommendation  29
To  reduce  hypoparathyroid  risk  during  central  neck
dissection,  hyperselective  hemostasis  is  recommended
after  identiﬁcation  of  the  parathyroid  glands  (grade  C).
Recommendation  30
If  a  parathyroid  gland  is  resected  during  central  neck
dissection,  it  should  be  reimplanted,  having  checked
that  it  is  not  a  metastatic  node:  extemporaneous
examination  may  be  useful  in  case  of  doubt  (grade  C).
Recommendation  31
Neuromonitoring  is  recommended  in  case  of
scheduled  extensive  bilateral  surgery  and/or  pre-
operative  unilateral  palsy  (grade  C).
Recommendation  32
Ahead  of  any  neck  dissection,  patients  should  be
informed  of  the  possible  associated  complications.
Complications  associated  with  central  and  with  lateral
dissection  should  be  distinguished  (grade  B).
Recommendation  33
So-called  ‘‘level  VII’’  is  deﬁned  above  by  the  tra-
cheal  projection  of  the  sternal  manubrium,  laterally  by
the  brachiocephalic  and  left  common  carotid  arteries,
and  below  by  the  tracheal  projection  of  the  aortic
arch  and  origin  of  the  brachiocephalic  artery  (grade  A)
(Fig.  2).
Recommendation  34
In  level  VII  lymph-node  metastasis,  it  is  essential  to
identify  an  at-risk  group.  Locally  advanced  DTC  (>  2
with  extrathyroid  invasion:  T3—T4),  uni-  or  bi-lateral
clinical  lymph-node  metastasis,  or  level  VI  lymph-node
metastasis  raise  suspicion  of  mediastinal  lymph-node
metastasis  (grade  B).
Figure  2  Cervico-mediastinal  junction  specimen,  deﬁned
above  by  the  thyroid  body  and  below  by  the  aortic  arch.  RBCV:
right  brachiocephalic  vein;  BCA:  brachiocephalic  artery;  LCCA:
left common  carotid  artery;  LSCA:  left  subclavian  artery;  LBCV:
left brachiocephalic  vein.
Dissection  by  Dr  Berthet.
Recommendation  35
Complete  level  VII  (prevascular  and  peritracheal)
cellulo-nodal  dissection  cannot  be  achieved  by  simple
caudal  extension  of  central  cervical  lymphadenectomy
via  the  transverse  cervicotomy.  Optimal  (en-bloc)  and
exhaustive  level  VII  neck  dissection  (beyond  the  left
brachiocephalic  vein)  requires  manubriotomy  extend-
ing  into  the  third  intercostal  space;  a  multidisciplinary
approach  is  recommended  for  this  level  (grade  A).
Recommendation  36
The  interest  of  combining  video-mediastinoscopy
in  attempted  mediastinal  dissection  via  cervicotomy
needs  to  be  assessed  (expert  opinion).
Recommendation  37
A.  Elective  mediastinal  dissection  is  not  indi-
cated  except  in  case  of  adenopathy  suspected  on
pre-operative  examination,  notably  because  overall
survival  is  not  improved  (grade  B).
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B.  In  case  of  risk  factors  (see  above),  contrast-
enhanced  radiology  exam  should  be  systematic.
According  to  thoracic  oncologic  malignancy  criteria,
any  mediastinal  adenopathy  greater  than  1  cm  on  the
shortest  axis  is  to  be  suspected  of  malignancy  (grade  C).
C.  In  massive  mediastinal  involvement  with  clear
clinical  or  histological  (aggressive  variant)  aggression
criteria  or  in  case  of  recurrence  after  initial  treatment
(surgery  and  radiation  therapy),  full-scale  mediasti-
nal  dissection  should  be  performed  on  the  principles
described  above  (grade  B).
D.  Mediastinal  picking  by  caudal  extension  of  central
dissection  is  not  recommended  (grade  B).
E.  Suspected  mediastinal  adenomegaly  on  pre-
operative  assessment  provides  the  only  indication
for  full-scale  level  VII  neck  dissection  on  a  direct
manubriotomy  approach.  The  procedure  requires  a
multidisciplinary  team,  including  a  thoracic  surgery
team  in  particular  (grade  B).
irst-line 131I radiation  therapy
irst-line 131I  radiation  therapy  is  indicated  whenever  tumor
xtension  on  the  TNM  classiﬁcation  and/or  multifocality
nd/or  aggressive  histological  type  suggest  residual  dis-
ase,  remote  extension  or  risk  of  subsequent  evolution  [1,2]
consensus  guidelines).
Recommendation  38
Lymph-node  status  is  to  be  taken  into  account  in
indicating  radio-iodine  treatment,  but  is  not  the  sole
decision  criterion  (grade  B).
articular  circumstances
n  papillary  microcarcinoma,  what  should  be  the  per-  and
ostoperative  attitude  toward  the  lymph-node  areas?
Recommendation  39
A.  In  per-operatively  conﬁrmed  T1-T2  cN0  cancer,
at  least  unilateral  central  dissection  is  recommended.
It  should  be  performed  by  a  trained  surgeon.  It  deter-
mines  pN  staging  (grade  B).
B.  Central  dissection  contralateral  to  the  tumor
is  optional.  It  should  be  performed  when  inferior
laryngeal  nerve  integrity  is  certain  and  a  functional
parathyroid  has  been  conserved.  Lymph-node  surgery
should  begin  ipsilaterally  to  the  tumor  (expert  opinion).B.  Guerrier  et  al.
Recommendation  40
If  papillary  microcarcinoma  is  discovered  on  deﬁni-
tive  histology  with  no  severity  factors,  no  neck
dissection  is  recommended  (grade  B).
articularities  relating  to  extension  of  histologic  variants
apillary  thyroid  cancer  is  generally  associated  with  a  good
rognosis,  but  there  exist  certain  ‘‘aggressive’’  variants:
ncocyte,  clear-cell,  diffuse  sclerosing,  tall-cell,  colum-
ar  cell,  solid,  cribriform  morular,  papillary  with  insular
omponent,  papillary  with  squamous  or  mucoepidermoid
omponent,  papillary  with  spindle  or  giant  cell  components,
nd  composite  papillary-medullary  variants.
Vesicular  carcinoma,  on  the  other  hand,  is  much  less
ymphophilic  than  papillary  carcinoma,  with  a  0—10%  rate
f  lymph-node  involvement  at  presentation  [33,34]  (level
f  evidence,  4).  Tumor  multifocality  and  clearly  invasive
esicular  carcinoma  are  the  two  risk  factors  for  initial  lymph-
ode  invasion  [33]  (level  of  evidence,  4).
Recommendation  41
A.  If  histology  ﬁnds  an  aggressive  papillary  variant,
a  maximalist  surgical  attitude  is  recommended  with
respect  to  the  lymph-node  areas  (expert  opinion).
B.  Vesicular  carcinoma  only  rarely  leads  to  lymph-
node  involvement,  and  lymph-node  surgery  is  of  little
beneﬁt.  In  multifocal  and/or  locally  invasive  forms,
however,  lymph-node  surgery  is  recommended  (grade
C).
anagement  of  lymph-node  recurrence
n  case  of  Tg  elevation  during  follow-up,  ultrasound  and 131I
cintigraphy  should  be  performed  with,  in  some  cases,  CT  or
RI.  Results  will  be  negative  in  a  quarter  of  cases.  PET-CT  is
ormally  indicated  in  this  situation  [35]  (level  of  evidence,
).
Recommendation  42
In  post-treatment  follow-up  of  DTC,  elevated  Tg
without  target  on  complete  imaging  assessment  is
a  contraindication  for  elective  lymph-node  surgery
(grade  B).
Recommendation  43
In  lymph-node  recurrence  targeted  on  pre-operativeassessment  in  the  lateral  cervical  compartment,  full-
scale  compartmental  dissection  including  the  target  is
recommended  if  no  extra  risk  is  associated  with  surgery
(grade  B).
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Recommendation  44
A.  Central  compartment  revision  surgery  for  lymph-
node  recurrence  should  be  targeted  (grade  B).
B.  It  requires  optimal  guidance,  with  at  least  con-
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[16] Frates MC, Benson CB, Charboneau JW, et al. Management
of thyroid nodules detected at US: Society of radiologistsventional  imaging  and  nuclear  imaging  with  image
fusion  (grade  C).
Most  teams  recommend  neuromonitoring  to  facilitate
inferior  laryngeal  nerve  identiﬁcation  in  such  revision
surgery  [36—38]  (level  of  evidence,  4).
Recommendation  45
Inferior  laryngeal  nerve  neuromonitoring  is  recom-
mended  in  central  compartment  lymph-node  revision
surgery  (grade  B).
Recommendation  46
A.  Repeat 131I  treatment  may  be  considered  after
surgical  revision.  If  surgery  is  not  indicated,  radio-
iodine  therapy  should  be  performed.
B.  In  case  of  persistent  ﬁxation  after  a  therapeutic
dose  of 131I  on  scintigraphy,  radio-iodine  therapy  may
be  repeated.
Refractory  tumor
DTC  is  considered  refractory  in  the  absence  of 131I  ﬁxation,
in  case  of  progression  following  radio-iodine  therapy  or  as
of  a  cumulative  dose  of  22  GBq  (600  mCi)  [39]  (consensus
guidelines).
Recommendation  47
In  refractory  tumor  with  non-resectable  adenopa-
thy,  treatment  options  are  either  external  radiation
therapy  or  participation  in  a  therapeutic  trial  (grade
B).
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